Theralase Technologies (TSE:TLT) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Theralase Technologies has launched a new clinical study site at St. Joseph’s Healthcare Hamilton for its bladder cancer treatment using Ruvidar, achieving a complete response rate of over 61% in its Phase II trials. The company’s innovative anti-cancer therapy has shown promising results in treating BCG-Unresponsive Non-Muscle Invasive Bladder Cancer, with a total response rate of over 68%.
For further insights into TSE:TLT stock, check out TipRanks’ Stock Analysis page.